1609575-99-6

Basic information

• Product Name: N-(4-fluorobenzyl)-2-(benzyloxy)-3-hydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide
• Synonyms: N-(4-fluorobenzyl)-2-(benzyloxy)-3-hydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide
• CAS NO: 1609575-99-6
• Molecular Weight: 463.422
• Mol File: 1609575-99-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(4-fluorobenzyl)-2-(benzyloxy)-3-hydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-fluorobenzyl)-2-(benzyloxy)-3-hydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide(1609575-99-6)
• EPA Substance Registry System: N-(4-fluorobenzyl)-2-(benzyloxy)-3-hydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide(1609575-99-6)

Safety Data

• Hazardous Substances Data: 1609575-99-6(Hazardous Substances Data)

Upstream product

• 186390-71-6 2-(carboxy-5-nitro-phenyl)malonic acid dimethyl ester 
• 1609575-88-3 methyl 2-{1-[(benzyloxy)amino]-3-methoxy-1,3-dioxopropan-2-yl}-4-nitrobenzoate 
• 1609575-93-0 methyl 2-(benzyloxy)-3-hydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxylate 
• 140-75-0 para-fluorobenzylamine 
• 16426-64-5 2-bromo-4-nitrobenzoic acid 

Downstream Products

• 1609576-08-0 N-(4-fluorobenzyl)-2,3-dihydroxy-6-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide 

Relevant articles and documents

Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2 H,4 H)-diones as human immunodeficiency virus type 1 integrase inhibitors

We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.